The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.
Increasing numbers of human immunodeficiency virus (HIV)-infected women are now accessing life-prolonging highly active antiretroviral therapy (HAART) in developing countries. There is a need for better understanding of interactions of human papillomavirus (HPV) and HIV, especially in the context of increasing life expectancy due to HAART. The data regarding the impact of HAART on reducing the incidence and progression and facilitating the regression of HPV infection and cervical abnormalities is largely inconsistent. Published studies differ in their study designs (prospective or retrospective cohorts or record linkage studies), screening and diagnostic protocols, duration and type of HAART use, recruitment and referral strategies, and definitions of screening test and disease positivity. Due to the ethical and resource limitations in conducting randomized trials of the impact of HAART on incidence of HPV, CIN, and cervical cancer among HIV-infected women, it is important to consider innovative study designs, including quasi-experimental trials and operations research in sentinel populations to answer the critical research questions in this area.
Bratcher
Lara F
LF
Institute for Global Health and Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, USA. vikrant.sahasrabuddhe@vanderbilt.edu.
Sahasrabuddhe
Vikrant V
VV
Ann Trop Med Parasitol. 2006 Jul-Sep;100(5-6):481-99
16899150
J Antimicrob Chemother. 2008 Jan;61(1):191-4
17977910
Br J Cancer. 2009 Mar 10;100(5):840-7
19223894
J Natl Cancer Inst. 2007 Jun 20;99(12):962-72
17565153
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):274-82
19387354
Ann Intern Med. 2000 May 16;132(10):810-9
10819705
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Infect Dis. 2003 Aug 15;188(4):555-63
12898443
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):412-8
16010162
J Natl Cancer Inst. 2005 Apr 20;97(8):577-86
15840880
Gynecol Oncol. 2008 Sep;110(3):402-7
18556050
N Engl J Med. 2009 Jul 16;361(3):305; author reply 306
19610158
AIDS. 2009 Mar 27;23(6):N1-5
19279439
AIDS. 2002 Apr 12;16(6):927-9
11919496
Antivir Ther. 2006;11(8):1091-6
17302379
AIDS. 2001 Nov 9;15(16):2157-64
11684935
AIDS. 2006 Aug 1;20(12):1645-54
16868446
BMC Cancer. 2008 Jul 25;8:211
18657270
J Natl Cancer Inst Monogr. 2003;(31):41-6
12807944
J Infect Dis. 2003 Jul 1;188(1):128-36
12825181
AIDS. 1998 Aug 20;12(12):1459-64
9727566
Intervirology. 1993;36(2):57-64
8294182
Br J Dermatol. 2010 Jan;162(1):6-11
19709102
Obstet Gynecol. 2009 Jan;113(1):26-31
19104356
Int J Cancer. 2000 Jan 15;85(2):206-10
10629079
Anticancer Res. 2007 Jul-Aug;27(4A):1795-8
17649775
JAMA. 2000 Feb 23;283(8):1031-7
10697063
Vaccine. 2009 Jan 14;27(3):337-47
19007840
AIDS Res Hum Retroviruses. 2007 Aug;23(8):965-71
17725412
Top HIV Med. 2007 Aug-Sep;15(4):130-3
17720998
J Clin Pathol. 2008 Jan;61(1):84-8
17483251
Acta Biomed. 2007;78(1):36-40
17687815
AIDS. 1996 Jun;10(7):759-64
8805867
Cancer. 2009 Feb 1;115(3):524-30
19127538
J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):377-80
11317082
J Infect Dis. 2001 Sep 1;184(5):547-51
11494160
Gynecol Oncol. 1993 Feb;48(2):210-3
8381376
Infect Dis Clin North Am. 2007 Mar;21(1):1-17, vii
17502227
AIDS. 2002 Sep 6;16(13):1799-802
12218392
Nat Rev Cancer. 2004 Nov;4(11):861-75
15516959
Am J Prev Med. 2007 Aug;33(2):134-6
17673101
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
11078759
Int J Cancer. 2008 Jul 1;123(1):187-94
18435450
J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6
15265968
J Pathol. 1999 Sep;189(1):12-9
10451482
Am J Obstet Gynecol. 2001 Mar;184(4):538-43
11262450
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
15770006
Virus Res. 1993 Feb;27(2):133-45
8384765
Clin Infect Dis. 2007 Aug 15;45(4):510-3
17638204
Clin Infect Dis. 2004 Mar 1;38(5):737-42
14986260